Can-Fite BioPharma
About Science Pipeline Investor Information Contact Us

Investor Information

Investor Information

Profile

Business Description

Can-Fite BioPharma Ltd. is an advanced clinical stage drug development company with a platform technology that addresses multi-billion markets in the treatment of inflammatory diseases, cancer, sexual dysfunction, and ophthalmic indications. The Company is conducting Phase I, II and III clinical trials for numerous indications in the U.S., Europe and Israel. CF102, the Company’s liver cancer drug now in Phase II, has been granted Orphan Drug Status by the U.S. FDA and has shown proof of concept to potentially treat four other cancers. CF101, which is in Phase II and III to treat inflammatory and ophthalmic diseases, has an excellent safety profile with experience in over 1,000 patients. Can-Fite currently maintains 14 patent families that include 74 international patents issued and pending and its science is well-founded with articles in 48 peer reviewed journals.

Address:
10 Bareket Street, Kiryat Matalon
P.O. Box 7537
Petah-Tikva, 49170

Website:
http://www.canfite.com/

Email:
info@canfite.co.il

Telephone:
+972-3-9241114

Fax:
+972-3-9249378

Details

CEO:
Pnina Fishman, Ph.D.

Issue Type:
On the OTCQB U.S. ADRs are traded at a ratio of 1 ADR = 2 common shares

Auditors:
Ernst & Young Israel

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

Sub-Industry:
Biotechnology

NAICS:
541711

SIC:
2834